Rapidly Enlarging Parotid Mass in a Person Living with HIV: A Case of Multiple Myeloma with Extramedullary Plasmacytoma.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
03 Aug 2023
03 Aug 2023
Historique:
medline:
4
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
BACKGROUND The differential diagnosis for a parotid mass is broad, including infectious, autoimmune, and neoplastic etiologies. In people with HIV, regardless of viral suppression or immune status, neoplastic causes are more common. This report describes the evaluation of a woman with a large parotid mass, with an ultimate diagnosis of multiple myeloma with extramedullary plasmacytoma. CASE REPORT A 51-year-old woman with HIV infection presented with headache, weight loss, and right facial mass that was present for 5 years but more rapidly enlarging in the prior year. CD4 count was 234 cells/mL, and HIV RNA was 10 810 copies/mL. Physical examination was significant for a large deforming right-sided facial mass, decreased sensation in the V1 and V2 distributions, and right-sided ophthalmoplegia and ptosis. MRI and PET/CT scan confirmed a metabolically active large parotid mass with extension into the cavernous sinus. An IgG kappa monoclonal spike was present on serum protein electrophoresis. Incisional biopsy of the facial mass showed atypical lymphoid cells with plasmablastic and plasmacytic morphology with a high mitotic rate and proliferation index. She was diagnosed with R-ISS stage II IgG kappa multiple myeloma with extramedullary plasmacytoma, and initiated on chemotherapy, radiation, and antiretroviral therapy. CONCLUSIONS A rapidly enlarging parotid mass should prompt timely evaluation and biopsy for definitive diagnosis, particularly in immunocompromised patients, including people with HIV. Extramedullary plasmacytomas have a more aggressive disease process in people with HIV and are associated with high-risk multiple myeloma and progression, as seen in this patient.
Identifiants
pubmed: 37533236
pii: 938431
doi: 10.12659/AJCR.938431
pmc: PMC10411289
doi:
Substances chimiques
Immunoglobulin G
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e938431Références
Exp Mol Pathol. 2011 Feb;90(1):85-90
pubmed: 20969860
Clin Rheumatol. 2010 May;29(5):525-9
pubmed: 20174847
Cells. 2021 Mar 31;10(4):
pubmed: 33807303
Leuk Lymphoma. 2002 Aug;43(8):1691-3
pubmed: 12400615
Am J Case Rep. 2021 Nov 23;22:e934311
pubmed: 34813583
Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):849-56
pubmed: 15262762
CMAJ. 2014 Oct 21;186(15):E579-86
pubmed: 24566651
J Community Hosp Intern Med Perspect. 2019 Feb 11;9(1):25-28
pubmed: 30788071
World J Surg Oncol. 2010 Mar 30;8:24
pubmed: 20353573
Am J Clin Pathol. 2018 Jul 03;150(2):168-176
pubmed: 29868855
Acta Otorhinolaryngol Ital. 2015 Oct;35(5):314-20
pubmed: 26824912
Head Neck Pathol. 2010 Jun;4(2):148-51
pubmed: 20512642
Case Rep Ophthalmol. 2016 May 10;7(1):274-8
pubmed: 27462255
Ann Rheum Dis. 2007 Jan;66(1):107-12
pubmed: 16728458
Adv Exp Med Biol. 2018;1040:23-27
pubmed: 28889233
J Craniofac Surg. 2003 Jan;14(1):37-40
pubmed: 12544218
Blood Lymphat Cancer. 2022 Apr 29;12:31-45
pubmed: 35517869
Arch Plast Surg. 2015 May;42(3):380-3
pubmed: 26015903
J Acquir Immune Defic Syndr. 2009 Dec;52(5):611-22
pubmed: 19770804
Mod Pathol. 2005 Jun;18(6):806-15
pubmed: 15578069
J Oral Maxillofac Pathol. 2014 May;18(2):286-90
pubmed: 25328314
Lancet. 2007 Jul 7;370(9581):59-67
pubmed: 17617273
Ann Oncol. 2010 Feb;21(2):325-330
pubmed: 19633044
J Oral Pathol Med. 2010 May;39(5):435-9
pubmed: 20537055
J Natl Cancer Inst. 2022 Jun 13;114(6):854-862
pubmed: 35292820
Front Surg. 2018 May 11;5:39
pubmed: 29868604
Clin Infect Dis. 2018 Aug 1;67(4):485-492
pubmed: 29617957
Transfus Med Hemother. 2009;36(1):32-39
pubmed: 21048819
Lancet. 2008 Mar 15;371(9616):932-44
pubmed: 18342688
Int J Clin Pediatr Dent. 2020 May-Jun;13(3):284-287
pubmed: 32904077
Case Rep Ophthalmol Med. 2018 Oct 21;2018:4746050
pubmed: 30420931
Biomark Res. 2013 Feb 04;1(1):8
pubmed: 24252328
Biomedicines. 2018 Mar 07;6(1):
pubmed: 29518985
Clin Oncol (R Coll Radiol). 2004 Sep;16(6):405-13
pubmed: 15487132
Insights Imaging. 2019 May 21;10(1):56
pubmed: 31115699
Head Face Med. 2009 Jan 20;5:4
pubmed: 19152712
Can J Ophthalmol. 2022 Feb;57(1):e22-e24
pubmed: 34384741
J Clin Neurosci. 2017 Nov;45:134-135
pubmed: 28765059
Neurochirurgie. 2012 Feb;58(1):37-9
pubmed: 22088574
Biomed Rep. 2020 Oct;13(4):28
pubmed: 32765867